

Ronald Andrew Seaton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3597034/publications.pdf>

Version: 2024-02-01

37
papers

2,273
citations

331670

21
h-index

377865

34
g-index

42
all docs

42
docs citations

42
times ranked

2857
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , 2019, 380, 425-436.	27.0	548
2	Late Ebola virus relapse causing meningoencephalitis: a case report. <i>Lancet, The</i> , 2016, 388, 498-503.	13.7	291
3	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe, The</i> , 2021, 2, e354-e365.	7.3	216
4	Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1053-1062.	3.0	165
5	Antimicrobial stewardship in wound care: a Position Paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3026-3035.	3.0	117
6	Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. <i>Journal of Infection</i> , 2020, 81, 952-960.	3.3	79
7	Clinical experience with daptomycin in Europe: the first 2.5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 912-919.	3.0	72
8	Outpatient parenteral antibiotic therapy: Principles and practice. <i>European Journal of Internal Medicine</i> , 2013, 24, 617-623.	2.2	71
9	Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 243-248.	2.5	70
10	Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. <i>JAC-Antimicrobial Resistance</i> , 2019, 1, dlz026.	2.1	58
11	Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience. <i>Advances in Therapy</i> , 2015, 32, 1192-1205.	2.9	54
12	Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections. <i>Infection and Drug Resistance</i> , 2016, 9, 47.	2.7	54
13	Antimicrobial point prevalence surveys in two Ghanaian hospitals: opportunities for antimicrobial stewardship. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa001.	2.1	53
14	Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 764-767.	3.0	49
15	Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in East Africa: red alert or red herring?. <i>BMC Infectious Diseases</i> , 2019, 19, 596.	2.9	48
16	Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORESM database. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1642-1649.	3.0	40
17	Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 18.	3.8	37
18	Outpatient parenteral antimicrobial therapy: updated recommendations from the UK. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3125-3127.	3.0	27

#	ARTICLE	IF	CITATIONS
19	Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Health Technology Assessment, 2019, 23, 1-92.	2.8	27
20	Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open, 2021, 11, e049733.	1.9	26
21	Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience. International Journal of Antimicrobial Agents, 2013, 41, 468-472.	2.5	23
22	A multicentre point prevalence survey of hospital antibiotic prescribing and quality indices in the Kurdistan regional government of Northern Iraq: the need for urgent action. Expert Review of Anti-Infective Therapy, 2021, 19, 805-814.	4.4	23
23	Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey. Pathogens and Global Health, 2022, 116, 421-427.	2.3	22
24	Outpatient parenteral antimicrobial therapy (OPAT) in the UK: findings from the BSAC National Outcomes Registry (2015-19). Journal of Antimicrobial Chemotherapy, 2022, 77, 1481-1490.	3.0	17
25	Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 305-311.	2.9	15
26	Mechanisms affecting the implementation of a national antimicrobial stewardship programme; multi-professional perspectives explained using normalisation process theory. Antimicrobial Resistance and Infection Control, 2020, 9, 99.	4.1	13
27	Assessment of the stability of citrate-buffered piperacillin/tazobactam for continuous infusion when stored in two commercially available elastomeric devices for outpatient parenteral antimicrobial chemotherapy: a study compliant with the NHS Yellow Cover Document requirements. European Journal of Hospital Pharmacy, 2020, , eihpharm-2020-002340.	1.1	11
28	Recent innovations and new applications of outpatient parenteral antimicrobial therapy. Expert Review of Anti-Infective Therapy, 2021, 19, 55-64.	4.4	10
29	Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy. JAC-Antimicrobial Resistance, 2021, 3, dlab141.	2.1	9
30	Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin. International Journal of Antimicrobial Agents, 2016, 47, 357-361.	2.5	6
31	Antibiotic prescribing for respiratory tract infection in patients with suspected and proven COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals. JAC-Antimicrobial Resistance, 2021, 3, dlab078.	2.1	6
32	Survey of delivery of parenteral antimicrobials in non-inpatient settings across Europe. International Journal of Antimicrobial Agents, 2022, 59, 106559.	2.5	5
33	Antibiotic use towards the end of life: development of good practice recommendations. BMJ Supportive and Palliative Care, 2021, , bmjpspcare-2020-002732.	1.6	4
34	Antimicrobial use at the end of life: a scoping review. BMJ Supportive and Palliative Care, 2020, , bmjpspcare-2020-002558.	1.6	3
35	Bio-hazards and drug reactions: A cautionary tale. Scandinavian Journal of Infectious Diseases, 2005, 37, 312-313.	1.5	2
36	Associations between declining antibiotic use in primary care in Scotland and hospitalization with infection and patient satisfaction: longitudinal population study. Journal of Antimicrobial Chemotherapy, 2022, 77, 2561-2568.	3.0	2

#	ARTICLE	IF	CITATIONS
37	P15 Evaluation of the stability of temocillin in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy in accordance with the requirements of the UK NHS Yellow Cover Document. JAC-Antimicrobial Resistance, 2022, 4, .	2.1	0